Sanofi will acquire Translate Bio for approximately $3.2bn, or $38.00 per share in cash
News
EC approves BMS’ Opdivo as adjuvant treatment for oesophageal or GEJ cancer patients
The approval is based on Phase III results from the CheckMate-577 trial
AZ’s Saphnelo scores US approval for systemic lupus erythematosus
Saphnelo is the first type I interferon receptor agonist to receive regulatory approval
UCB’s bimekizumab issued NICE recommendation for severe plaque psoriasis
Bimekizumab is the first to follow NICE’s new expedited appraisal process
More than 85 million COVID vaccines administered across the UK, reports DHSC
Over 88% of adults have had a first dose and over 72% both doses
GSK’s Nucala approved to treat chronic rhinosinusitis with nasal polyps
Nucala is the first IL-5 inhibitor to be approved for adult CRSwNP patients in the US
NICE publishes ‘rapid’ guideline on rare blood clots associated with COVID-19 jab
Although condition is extremely rare, it requires ‘swift diagnosis and urgent treatment’ says NICE
UK genomics market valued at over £5bn, according to new report
‘Genomics Nation’ report launched in a bid to showcase the thriving UK genomics sector
GPs call for rescue plan to ‘save’ general practice in the UK
RCGP’s chair said that general practice in the UK is currently at a ‘breaking point’
Sanofi, Regeneron’s Dupixent wins positive results in chronic spontaneous urticaria
CSU is the fifth disease for which Dupixent has positive Phase III data, according to Sanofi and Regeneron
Ipsen to collaborate with BAKX Therapeutics on early-stage oncology asset
BKX-001 is designed to target the apoptosis, or programmed cell death, pathway
New study provides insight into the pharma industry’s reputation in the UK
Findings come from a year-long study into the perceptions of the pharma sector in the UK
Macomics secures £4.24m to accelerate macrophage-based therapeutics portfolio
The company was co-founded in 2019 by Jeffrey Pollard and Luca Cassetta of the University of Edinburgh
AC Immune acquires Parkinson’s disease vaccine candidate
AC Immune is set to acquire Affiris’ entire portfolio of therapeutics targeting alpha-synuclein
Study shows AZ’s COVID-19 jab did not increase the rate of rare blood clots after second dose
Rate of rare blood clots with low platelets after the second dose is comparable to background rates observed in unvaccinated populations
